Abstract:Objective: While the molecular events controlling insulin secretion from β-cells have been documented in detail, the exact mechanisms governing glucagon release by α-cells are understood only partially. This is a critical knowledge gap, as the normal suppression of glucagon secretion by elevated glucose levels fails in type 2 diabetes (T2D) patients, contributing to hyperglycemia through stimulation of hepatic glucose production. A critical role of glycolytic flux in regulating glucagon secretion was supported by recent studies in which manipulation of the activity and expression of the glycolytic enzyme glucokinase altered the setpoint for glucose-suppression of glucagon secretion (GSGS). Given this precedent, we hypothesized that genetic activation of glucokinase specifically in α-cells would enhance GSGS and mitigate T2D hyperglucagonemia. Methods: We derived an inducible, α-cell-specific glucokinase activating mutant mouse model (GckLoxPGck∗/LoxPGck∗; Gcg-CreERT2; henceforth referred to as "α-mutGCK") in which the wild-type glucokinase gene (GCK) is conditionally replaced with a glucokinase mutant allele containing the ins454A activating mutation (Gck∗), a mutation that increases the affinity of glucokinase for glucose by almost 7-fold. The effects of α-cell GCK activation on glucose homeostasis, hormone secretion, islet morphology, and islet numbers were assessed using both in vivo and ex vivo assays. Additionally, the effect of α-cell GCK activation on GSGS was investigated under diabetogenic conditions of high-fat diet (HFD) feeding that dysregulate glucagon secretion. Results: Our study shows that α-mutGCK mice have enhanced GSGS in vivo and ex vivo, independent of alterations in insulin levels and secretion, islet hormone content, islet morphology, or islet number. α-mutGCK mice maintained on HFD displayed improvements in glucagonemia compared to controls, which developed the expected obesity, glucose intolerance, elevated fasting blood glucose, hyperinsulinemia, and hyperglucagonemia. Conclusions: Using our novel α-cell specific activation of GCK mouse model, we have provided additional support to demonstrate that the glycolytic enzyme glucokinase is a key determinant in glucose sensing within α-cells to regulate glucagon secretion. Our results contribute to our fundamental understanding of α-cell biology by providing greater insight into the regulation of glucagon secretion through α-cell intrinsic mechanisms via glucokinase. Furthermore, our HFD results underscore the potential of glucokinase as a druggable target which, given the ongoing development of allosteric glucokinase activators (GKAs) for T2D treatment, could help mitigate hyperglucagonemia and potentially improve blood glucose homeostasis.

An emerging direction in glucagon-based therapy

Glucagon receptor monoclonal antibodies: A new strategy for diabetes pharmacotherapy

Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose

Glucagon Switches between GLP-1 and Glucagon Receptors in Normal and Hyperglycemic Mice

Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases

Characterization of a naturally occurring mutation V368M in the human glucagon receptor and its association with metabolic disorders

Glucagon Potentiates Insulin Secretion Via Beta-Cell Gcgr At Physiological Concentrations Of Glucose

Glucagon Receptor Antagonist Upregulates Circulating GLP-1 Level by Promoting Intestinal L-cell Proliferation and GLP-1 Production in Type 2 Diabetes

The Regulation and Secretion of Glucagon in Response to Nutrient Composition: Unraveling Their Intricate Mechanisms

Γ‐glutamylcysteine Alleviates Insulin Resistance and Hepatic Steatosis by Regulating Adenylate Cyclase and IGF‐1R/IRS1/PI3K/Akt Signaling Pathways

Intra-islet glucagon signalling regulates beta-cell connectivity, first-phase insulin secretion and glucose homeostasis

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity

Vitamin D binding protein/GC-globulin: a novel regulator of alpha cell function and glucagon secretion

Antagonistic Glucagon Receptor Antibody Promotes Α-Cell Proliferation and Increases Β-Cell Mass in Diabetic Mice

Hepatic Glucagon Action - Beyond Glucose Mobilization

Targeting hepatic glutaminase activity to ameliorate hyperglycemia

Glucagon Receptor Antagonism Promotes the Production of Gut Proglucagon-Derived Peptides in Diabetic Mice.

Glucagon and Regulation of Glucose Metabolism

Pancreatic alpha cell glucagon–liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes

Genetic activation of α-cell glucokinase in mice causes enhanced glucose-suppression of glucagon secretion during normal and diabetic states